🔗 Share this article

Given that the United States continues making sweeping changes to its immunization schedules, an unexpected name appears in a surprising turn: Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the global health crisis and has zeroed in on potential fatalities following Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Program

Public health authorities were set to reveal major revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s national calendar, according to reports – a major change that would place the US at odds with a large portion of the world with insufficient data for improved outcomes. The announcement has been pushed back until the new year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this calendar year.

A Shift at the Regulatory Body

This interim role could signify a strengthened alliance between the drug and biologics centers as Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending specific childhood shot schedules in the US in order to be more similar to the Danish model, a society with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the purview of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

The appointee has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been standard for past directors of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who led the center have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just focuses on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and other areas, and each of these must be looked after,” she said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial administrative component to the position, which oversees over 5,000 staff members. “It is a huge management job, if you perform it correctly,” the former official added.

Response and Contentious Programs

Regarding inquiries about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among agency officials on vaccines, a representative stated that the “concerns rely on flawed presumptions”.

“Her resume is consistent with the responsibilities of her position,” the official said, pointing to the period Dr. Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial rapid therapy clearance system that reportedly concerned her former heads. “How are these drugs being selected for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent oversight of all drugs, with the exception of immunizations.”

Established Track Record on Immunizations

With immunizations, Høeg has a more documented, if problematic, history, Howard observe. She published a analysis using unconfirmed crowd-sourced reports to estimate the incidence of heart inflammation following Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are riskier than they are.

Part of her “policy goals” for the current administration featured altering guidelines for novel immunizations and ending “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has according to sources proposed barring young men from receiving COVID-19 vaccinations.

“She is an complete dogmatist who begins with her beliefs and reverse-engineers to retrofit the evidence in a very disingenuous, dishonest way,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other skeptics, {like|